Freestone Grove Partners’s Collegium Pharmaceutical COLL Stock Holding History

Freestone Grove Partners’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Sell	44,493 -14,153	-24%	-$484K	0.01%	454
2026 Q1	$1.94M	Buy	58,646 +46,735	+392%	+$1.98M	0.01%	375
2025 Q4	$551K	Sell	11,911 -9,243	-44%	-$387K	﹤0.01%	555
2025 Q3	$740K	Buy	+21,154	New	+$735K	0.01%	476
2025 Q2	–	Sell	-7,761	Closed	-$232K	–	704
2025 Q1	$232K	Sell	7,761 -3,380	-30%	-$103K	﹤0.01%	513
2024 Q4	$319K	Buy	+11,141	New	+$369K	﹤0.01%	456

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Freestone Grove Partners's COLL Position: Q2 2026 in Review

Freestone Grove Partners reduced its Collegium Pharmaceutical (COLL) stake by 24% in Q2 2026, selling an estimated $484K and leaving 44,493 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #454.

Freestone Grove Partners first reported a position in COLL in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.94M in Q1 2026. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Freestone Grove Partners held 44,493 shares of Collegium Pharmaceutical worth $1.61M as of Q2 2026.
Freestone Grove Partners sold 14,153 Collegium Pharmaceutical shares in Q2 2026, an estimated $484K.
Collegium Pharmaceutical made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #454 holding.
Freestone Grove Partners first reported a position in Collegium Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
Freestone Grove Partners's Collegium Pharmaceutical position peaked at $1.94M in Q1 2026.
280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.